Pharmacogenomic Reporting

Clinically Actionable Intelligence

Translational™  provides pharmacogenomic (PGx) reporting for drugs used in cardiology, psychiatry, neurology, pain treatment, oncology, and more. Our solutions transform pharmacogenetic test results into concise, actionable reports for physicians. Reports incorporate the latest guidance from scientific groups (e.g., the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)), governments (e.g., the Federal Drug Administration (FDA) and the European Medicines Agency (EMA)), and leading-edge science. Our experts carefully curate this information such that it can be delivered on-demand.

Get in Touch      We’ll help you translate from molecules to medicine.

How Genotype Affects Drug Response

Clinicians recognize that patients respond to medications in different ways. They are accustomed to trying multiple drugs to find one that works, and wondering whether lack of efficacy is a mask for noncompliance or even drug abuse. For many common prescriptions, a simple genetic test can provide insight into the likely efficacy or toxicity of a drug, allowing a physician to choose safer and more effective treatments. Avoiding the need to re-do a stent, preventing an adverse reaction, or reducing an elderly patient’s mental fog can all significantly reduce health care costs – not to mention quality of life for the patient. Approximately 18% of prescriptions in the U.S. are for drugs that have clinically actionable guidance for particular genotypes (Nature, 2015).

Supported Drugs and Genes | Sample Reports | Clinical Utility of Preemptive Testing 

Dark Daily Whitepaper - Pharmacogenomic Testing

A Lab Leader's Guide to Pharmacogenomic Testing (PGx)

Cloud-based software reporting of PGx for hospitals, health systems and clinical laboratories


Cascading effects

When a breastfeeding mother has a rapid metabolizer genotype, she can unintentionally pass on a deadly dose to her infant when given a drug like codeine, which is metabolized into morphine.  Understanding a mother’s phamacogenomic profile enables a physician to protect both mother and child. See: Lancet 2006,368:704

Predictive power

The HIV therapy Abacavir can produce life-threatening hypersensitivity in 5 to 8% of patients. The allele HLA-B*5701, present in only 1-5% of the population, is strongly predictive of this deadly response. When testing for this genotype occurs, alternative therapies can be chosen. See: Medscape 2015, NEJM 2008

Right drug, right patient

Plavix (clopidogrel) is standard of care for preventing deadly clotting, heart attack or stroke after coronary stent surgery. However, 2-14% of the population does not metabolize this medication adequately, leaving them vulnerable even when alternative drugs are available. See:  FDA Black Box Warning, 2010